❌ SB227
Cap cost sharing for prescription insulin drugs
Current Status: In Senate Committee (Financial Institutions, Insurance and Technology)
Summary
The bill caps cost sharing for prescription insulin drugs at thirty-five dollars per thirty-day supply for health plans issued or renewed after the effective date. This applies to all covered prescription insulin drugs used to treat diabetes. No penalties or exceptions are specified.
Rationale
The bill imposes a government mandate on health plans regarding pricing for insulin, which conflicts with the Libertarian principles of free markets and minimal government intervention in economic matters.
Risks and Concerns
- Increased government control over healthcare pricing
- Potential for reduced competition in the insulin market
- Encouragement of further government intervention in healthcare